Cellebrite Raises 2026 Adjusted EBITDA Guidance to $163–166 Million
Key Facts
Cellebrite raised its 2026 adjusted EBITDA guidance to a range of $163–166 million, with an expected margin of 29% to 30%, after reporting third-quarter results. The CEO said annual recurring revenue, revenue and adjusted EBITDA all ended the quarter above the company’s targets. Revenue reached $149 million, up 18% year over year, while annual recurring revenue reached $528.5 million, up 20%. The guidance increase reflects an improved estimate of annual profitability following quarterly performance, while the company did not raise its annual revenue range in tandem. EL7 data show the stock closed at $11.53 on November 13.
Management attributed revenue growth to strong international performance, accelerating U.S. federal activity and momentum gained by the Genesis platform in its first full quarter. The CEO said, "Revenue expansion was driven by strong international performance, further acceleration in the U.S. federal sector, and Genesis gaining meaningful momentum in its first full quarter." Subscription revenue reached $134.9 million, up 20% from the same period a year earlier. Dollar-based net recurring revenue retention was 116%. Genesis became available to public- and private-sector customers in Australia, the United Kingdom and the European Union, following its initial launch for local and state government agencies in North America on June 10, 2026. These markets extend the platform’s availability, while management described cloud and AI revenue as more recurring within its targeted revenue mix.
On quarterly profitability, the company posted net income of $26.7 million under U.S. generally accepted accounting principles and net income of $45.6 million under its non-GAAP measures. Adjusted EBITDA was $53.6 million, with a 36% margin. Free cash flow was $51.8 million for the quarter and $166 million for the 12 months ended with the third quarter, with a 30.9% margin. The CFO said the company expects a free cash flow margin of about 30% for the full year. The CFO added that the updated revenue targets reflect more recurring cloud and AI revenue and lower hardware revenue compared with the third quarter.
The results show revenue growth accelerating from the second quarter of 2026, when revenue was $131.1 million, up 16% year over year, while revenue in the third quarter of 2025 was about $126 million, up 18%. Annual recurring revenue rose from $507.8 million in the second quarter to $528.5 million in the third, while its year-over-year growth was 21% in the second quarter, compared with 19% in the third quarter of 2025. In the first nine months of 2026, revenue was $408.461 million, compared with $346.854 million in the same period of 2025. In August, the company had cut its annual revenue guidance to $555–561 million and raised its adjusted EBITDA range to $153–159 million. Management said at the time that annual recurring revenue came in below expectations because of longer sales cycles and less-than-expected expansion in Inseyets conversions.
After its third-quarter results, Cellebrite forecast annual revenue of $553 million to $558 million, equivalent to year-over-year growth of 16% to 17%, and kept its year-end annual recurring revenue guidance at $550–560 million, or growth of 14% to 16%. That means the announced revision covered adjusted EBITDA guidance, while the revenue and recurring revenue ranges remained at their stated levels. For the fourth quarter, the company expects revenue of $145 million to $150 million and adjusted EBITDA of $47 million to $50 million, with a margin of 32% to 33%. Management also said it still expects a free cash flow margin of about 30% for the full year. The proposed acquisition of Corellium remains under review by the Committee on Foreign Investment in the United States, as the company said it has not received a final, binding decision and cannot predict the outcome.